Hinge Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HNGE research report →
Range $80 – $140
Price Chart
About the company
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation.
- CEO
- Daniel A. Perez
- IPO
- 2025
- Employees
- 1,437
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on HNGE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.60B
- P/E
- 49.93
- Fwd P/E
- 42.01
- PEG
- 0.29
- P/S
- 10.54
- P/B
- 28.05
- EV/EBITDA
- 50.27
- Div Yield
- 0.00%
- Gross Margin
- 85.75%
- Op Margin
- 18.74%
- Net Margin
- 21.02%
- ROE
- 50.47%
- ROIC
- 44.92%
Latest fiscal year · YoY change
- Revenue
- $587.86M+50.6%
- Gross Profit
- $469.30M+56.1%
- Op Income
- $-546,371,000
- Net Income
- $-528,260,999-4326.9%
- EPS
- $-5.36-3473.3%
- OCF Growth
- +249.9%
- FCF Growth
- +277.5%
- 52W High
- $126.40
- 52W Low
- $30.08
- 50D MA
- $105.73
- 200D MA
- $72.56
- Beta
- 1.36
- RSI (14)
- 44
- Avg Volume
- 1.92M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Hinge Health reported another strong quarter with 52% revenue growth, record profitability, and raised full-year guidance on better-than-expected yield and continued commercial momentum.· November 2, 2026
- Revenue was $235 million, up 52% year over year, and above the quarter’s $223 million-$225 million guidance range.
- Gross margin reached 88%, up about 480 basis points year over year, while operating margin expanded to 33% from 20% last year.
- LTM calculated billings rose 54% to $960 million, supported by stronger yield and a larger installed base.
- Management raised full-year 2026 guidance to $879 million-$881 million of revenue and $266 million-$268 million of operating income.
- Commercial momentum stayed strong: 3,270 contracted clients, 3 new Fortune 15 wins, and almost 1 million SMB lives closed through Q3.
Q3 2026 revenue was $235 million, up 52% from $154 million in Q3 2025 and above the prior guidance range of $223 million-$225 million. Gross margin was 88%, up about 480 basis points year over year. Operating income was $77 million, equal to a 33% operating margin, up about 1,300 basis points year over year. Free cash flow was $120 million, a 51% margin, excluding $7 million of one-time acquisition-related payments; diluted EPS was $0.71. LTM calculated billings were $960 million, up 54% year over year. For Q4 2026, management guided to revenue of $249 million-$251 million and operating income of $81 million-$83 million. For full-year 2026, revenue guidance was raised to $879 million-$881 million and operating income guidance to $266 million-$268 million. Management expects end-of-year LTM average eligible lives of approximately 25.5 million and full-year yield of 4.6%.
Dan Perez framed the quarter as evidence that Hinge Health’s automated care model is working clinically, commercially, and financially. He emphasized that core MSK remains the largest and most underpenetrated opportunity, with 88% of lives in their markets still to be won, and said the company is extending the same platform into migraine and GI rather than starting from scratch. His tone was upbeat and confident, with a focus on long runway, durable growth, and a unified care platform.
James Budge highlighted that the quarter’s upside was driven by billings outperformance, which he said was driven by stronger yield. He pointed to targeted enrollment activity being up almost 75% year over year and member renewals up almost 25%, and linked gross margin expansion to reduced hardware costs, AI, and automation. He also detailed capital allocation, noting $358 million in cash and investments, $26 million spent repurchasing 296,000 shares, and $209 million of outflows from M&A and net share settlements, while saying the company remains well-capitalized. He reiterated that gross margin is still targeted at 85% next year, with operating margin expected to keep improving.
Analysts focused on HingeSelect, migraine, GI integration, ASP, margins, and the sustainability of yield gains. Management said HingeSelect is still early but traction is strong, with roughly doubled lives since Investor Day and about 5,500 provider locations, while client interest is high. On migraine and GI, management said adoption is tracking well, but meaningful revenue contribution is expected later, with the integrated GI product targeted for summer 2027 and more meaningful revenue contribution in 2028; ASP is expected to stay roughly flat in 2027 before potential uplift later. On margins, management said the business is gaining leverage from AI/automation and that SMB economics are somewhat better than enterprise, but gross margin is expected to level around 85% next year as the company continues investing in care delivery.
The bull case from this call is that Hinge Health is still growing rapidly while also improving profitability, with 52% revenue growth, 88% gross margin, and 51% free cash flow margin in the quarter. Management also sounded confident that yield gains, SMB traction, preferred-channel relationships, and cross-sell into migraine, GI, and HingeSelect can support growth beyond the core MSK business.
The main risk is that management itself said migraine and GI won’t materially affect billable activities until 2028, while ASP is expected to remain flat in 2027. HingeSelect is also described as a slower-burn product because the network still needs to be built out market by market, and management is targeting gross margin around 85% next year rather than expecting further major expansion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.8%
- Shares Outstanding
- 81.27M
- Float Shares
- 77.06M
of shares held by institutions
292 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.41M | ▲ 841.25K |
| Vanguard Group Inc | 2.61M | ▲ 1.37M |
| Two Sigma Investments, LP | 2.56M | ▲ 751.61K |
| Vanguard Capital Management LLC | 2.51M | ▲ 620.26K |
| Vanguard Portfolio Management LLC | 2.49M | ▲ 346.13K |
| Morgan Stanley | 2.45M | ▲ 839.46K |
| 11.2 Capital Management, LLC | 2.35M | ▼ 110.54K |
| Franklin Templeton Inc | 2.04M | ▲ 460.35K |
| Acadian Asset Management LLC | 1.97M | ▲ 904.39K |
| Assenagon Asset Management S.A. | 1.85M | ▲ 1.77M |
| Arrowstreet Capital, Limited Partnership | 1.85M | ▲ 733.74K |
| Fuller & Thaler Asset Management, Inc. | 1.77M | ▲ 57.49K |
Held by 344 ETFs
Biggest fund positions in HNGE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Robinson Elliott | sell | 0 |
| Nov 11, 26 | Mecklenburg Gabriel M.I. | other | 200,000 |
| Nov 11, 26 | Mecklenburg Gabriel M.I. | other | 200,000 |
| Nov 11, 26 | Mecklenburg Gabriel M.I. | sell | 104,525 |
| Nov 11, 26 | Mecklenburg Gabriel M.I. | sell | 67,873 |
| Nov 11, 26 | Mecklenburg Gabriel M.I. | sell | 16,615 |
| Nov 11, 26 | Mecklenburg Gabriel M.I. | sell | 8,607 |
| Nov 11, 26 | Mecklenburg Gabriel M.I. | sell | 2,380 |
| Nov 10, 26 | Budge James | sell | 1,900 |
| Nov 10, 26 | Budge James | sell | 7,601 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HNGE coverage
Recent articles, reports, and earnings notes.
No research on HNGE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HNGE report →IPO Stock Of The Week: Hinge Pulls Back To Key Support Level Amid Market Sell-Off
investors.com · Nov 20
Hinge Health: Improving Profitability Changes My Rating (Rating Upgrade)
seekingalpha.com · Nov 19
HNGE Stock Surges Nearly 146% YTD: Can Its Growth Story Continue?
zacks.com · Nov 18
Healthcare Stocks Overtake Tech: 5 Strong Buys Combining Growth And Value
seekingalpha.com · Nov 17
Add These 4 Top-Performing Liquid Stocks to Maximize Returns
zacks.com · Nov 16
Ashton Thomas Private Wealth LLC Acquires New Holdings in Hinge Health Inc. $HNGE
defenseworld.net · Nov 13
Earnings Estimates Rising for Hinge Health Inc. (HNGE): Will It Gain?
zacks.com · Nov 9
Best Momentum Stocks to Buy for November 9th
zacks.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.